When combined with cyclophosphamide (CTX), a treatment known to reduce immunosuppressive cues and favor the engraftment of newly transferred CD8 T cells26–28, the ACT of PHD2/3 KO CD8 T cells resulted in an even better anti-tumor response. This evidence concerns the gene EGLN1 and neoplasm.